Six mycoplasma strains, isolated under anaerobic conditions from the human oropharynx, were studied by biologic and serologic means. The strains produced nippled colonies with weak hemolytic activity for guinea pig erythrocytes on agar medium. In addition, the strains metabolized arginine with a concomitant alkaline shift in the pH of the medium but did not produce a pH shift when grown in the presence of glucose or urea. The strains failed to reduce 2-3-5 triphenyl tetrazolium and were inhibited by 0.001% methylene blue. In addition, they required fresh yeast extract for growth. When compared by several serologic methods, the strains were found to be related to each other but distinct from 23 serotypes of human, animal, and avian origin. However, one-way serologic relationships between one of the new strains and Mycoplasma orale type 1 and M. salivarium were observed when they were tested by complement fixation. Furthermore, partial relationship of one of the new strains to all of the arginine-utilizing mycoplasma species of human origin was demonstrated with the agar gel diffusion technique. Thus, the new strains appear to constitute a new mycoplasma species, for which the name M. orale type 3 is tentatively proposed. M. orale type 3 accounted for 1.4% of 437 mycoplasma isolates from the oropharynx of adults. The new species probably is a rare member of the normal mycoplasmal flora of man.
As a result of extensive studies of respiratory disease, a number of mycoplasmas which were serologically distinct from the previously recognized species were recovered from the oropharynx of children and adults. Several of these isolates were subsequently found to comprise two new mycoplasma species, Mycoplasma orale types 1 and 2 (23, 24) . We describe the biologic and serologic characteristics of six mycoplasma isolates which form a third new spe9ies, designated M. orale type 3.
MATERIALS AND METHODS Mycoplasmas. Prototype strains of mycoplasmas of human, animal, or avian origin were obtained, in most cases, from D. G. Edward or from the investigator who originally described the species (Table 1) . Mycoplasma isolates DC-333, DC-440, DC-752, DC-1114, DC-1302, and DC-1316 were obtained from the oropharynx of adult patients hospitalized at D.C. General Hospital, Washington, D.C. (13) . ' Present address: National Institutes of Health, National Institute of Neurological Diseases and Blindness, Extramural Programs, Bethesda, Md. 20014 Media. Either Hayflick's broth or agar medium was used for the isolation, propagation, and maintenance of mycoplasmas (la, 7) . For metabolic inhibition tests and nutritional studies of mycoplasmas, the medium was modified as described below.
Immunizing and complement-fixing mycoplasma antigens were prepared in rabbit infusion medium as previously described (26) . Agar cultures were incubated aerobically or in an atmosphere of 5% CO2 in N2 at 36 to 37 C; broth cultures were incubated aerobically.
Cloning of mycoplasma strains. Mycoplasmas were thrice-cloned by a procedure described previously (23) . In some cases, each cloning cycle was preceded by filtration of the mycoplasma broth culture through a 220-nm membrane filter (Millipore Corp., Bedford, Mass.) to assure that colonies represented the progeny of individual organisms.
Production of hyperimmune sera. Sera hyperimmune to large colony mycoplasmas were prepared in rabbits by a method described previously (26) . Antisera to T-strain mycoplasmas were prepared in guinea pigs from antigens grown in a modification of Hayflick's medium (16) .
Tests for utilization of substrates and requirements for nutrient factors. Mycoplasmas were cultivated for Hemolysis. Tests for hemolytic activity of mycoplasma colonies were performed with guinea pig erythrocytes by a method described previously (21) .
Serologic tests. Complement-fixation (CF) tests were performed as described previously (26) . We used exactly 1.7 units of complement with overnight fixation at 4 C.
Metabolic inhibiton tests were performed as described previously (15, 16, 25) . Briefly, the inhibition of mycoplasma growth by antiserum was measured with the inhibition of metabolism of a substrate (i.e., glucose, arginine, or urea) as an indirect measure of growth inhibition. In some cases, the test was performed with medium containing 1% PPLO Serum Fraction (Difco) instead of 20% horse serum. Fresh, frozen guinea pig serum or selected lots of lyophilized commercial guinea pig complement were employed when such additives were found to improve the sensitivity of the test.
Growth inhibition tests were performed, as described previously (2, 8) , by applying antiserumimpregnated filter-paper discs to the surface of agar medium, uniformly inoculated with a suspension of mycoplasmas. The agar medium was incubated for 2 to 5 days and then examined with a dissecting microscope for zones of growth inhibition surrounding the paper discs. In some cases, filter paper discs containing dried antiserum were employed (22) .
Agar gel diffusion tests were performed as described previously with 400-fold concentrates of mycoplasmas in agar gel immunoplates prepared by Hyland Laboratories, Los Angeles, Calif. (26 Table  2 ). Furthermore, strain DC-333 failed to reduce 2-3-5 triphenyl tetrazolium and was inhibited by methylene blue; these properties it shared with all the mycoplasmas of human origin, with the exception of M. pneumoniae (9; (Fig. 3) . M. salivarium antiserum produced at least one precipitin line shared by strain (Fig. 4) (Fig. 5-7) . However, the single line produced with M. fermentans antigen was much weaker than the lines produced with the other antigens (Fig. 5) .
Incidence of isolation and relationship to illness. Only six (1.4%) of 437 mycoplasmas isolated from the oropharynx of adults belonged to the same serotype as strain DC-333 (Table 5) . Furthermore, no mycoplasmas belonging to the new serotype were found among 816 mycoplasmas recovered from the oropharynx of children.
Two strains (DC-752 and DC-440) were recovered from patients with pneumonia (believed to be pneumococcal in etiology); the other four strains were recovered from patients with diseases of a noninfectious nature.
Furthermore, paired sera from patients who yielded strains DC-333, DC-440, DC-1302, or DC-1316 failed to fix complement with antigen prepared from strain DC-333. Thus, the new serotype does not appear to be a respiratory pathogen but, rather, a rare member of the normal oropharyngeal mycoplasma flora. b Approximately equal numbers of persons hospitalized with pneumonia and persons with diseases of a noninfectious nature (13) .
DISCUSSION
c Approximately equal numbers of persons with respiratory disease and persons with diseases of a noninfectious nature (1; J. G. Canchola, personal communication). medium when incubated in an atmosphere of 5 % CO2 in N2, metabolizes arginine but not urea or glucose (as judged by change in the pH of the medium), requires fresh yeast extract for growth, is inhibited by 0.001% methylene blue, and fails to reduce 2-3-5 triphenyl tetrazolium. In addition, the new serotype produces a-hemolysis of guinea pig erythrocytes. Others have shown that, under optimal conditions of testing, the arginineutilizing mycoplasmas of human origin produce ,8-hemolysis instead of ca-hemolysis and that the hemolysin is hydrogen peroxide (4, 19) . In one of these studies (19) , the DC-1114 strain of the new serotype was also found to produce ,B-hemolysis. It was shown, however, that the amount of hemolysin produced by the arginine-utilizing organisms, including the new serotype, was significantly less than that produced by M. pneumoniae under comparable conditions. Recently, in a study which confirmed and extended the findings of others (11; R. A. Del Giudice and R. Pavia, Bacteriol. Proc., p. 71, 1964), colonies of M. pneumoniae were found to adsorb erythrocytes from the rat, guinea pig, monkey, and chicken (20) . In addition, colonies of M. orake type 1 and strain DC-11 14 of the new serotype were found to adsorb chicken erythrocytes but not erythrocytes from the rat, guinea pig, or monkey (20) . Thus, the new serotype biologically resembles the arginine-utilizing species of mycoplasma, in general, and of M. orale type 1, in particular.
When compared serologically with the recognized mycoplasma species, the new serotype was found to be distinct. Thus, the new species shared some, but not all, antigens with the other arginine-utilizing mycoplasmas of human origin when tested by agar gel diffusion; in addition, it fixed complement in a one-way cross-relationship with M. salivarium and M. orale type 1, but it appeared to be entirely unrelated to these and other mycoplasmas when tested by the more specific growth-inhibition and metabolic-inhibition techniques.
Recently another new species of mycoplasma from man, designated M. lipophilia but subsequently renamed M. lipophilum, was discovered (R. A. Del Giudice and T. R. Carski, Bacteriol. Proc., p. 67, 1968, and Del Giudice, personal communication). We have compared M. lipophilum with the new serotype we are describing and have found it to be biologically and serologically distinct. In addition, the new mycoplasma represented by strain DC-333 was found to be serologically distinct from the previously described Navel strain, a mycoplasma serotype represented by a single isolate (18) .
Thus, a new serotype of mycoplasma, comprised of strains DC-333, DC-440, DC-752, DC-1114, DC-1302; and DC-1316, was found to be distinct from 23 mycoplasma serotypes of human, animal, and avian origin. Furthermore, preliminary biologic testing suggests that the new mycoplasma is unrelated to a number of other recently described mycoplasmas of animal and avian origin, including M. hyopneumoniae (M. suipneumoniae; 6, 12), M. synoviae (14) , M. anatis (17) , M. meleagridis (27) , M. bovirhinis (10) , M. felis, and M. gateae (3) .
On the basis of these findings, we propose that the new mycoplasma serotype be recognized as a new species, designated M. orale type 3, and that the type and representative strain of this species be DC-333. We believe that the proposed name adequately reflects the habitat of this mycoplasma and connotes its biologic and serologic similarity to M. orale type 1. 
